{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:16:01Z","timestamp":1788171361715,"version":"build-2803163510"},"reference-count":115,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Thyroid eye disease (TED) is a complex autoimmune disorder and the most common extrathyroidal manifestation of Graves\u2019 disease, characterized by orbital inflammation, tissue remodelling, and varying degrees of functional and cosmetic impairment. Although often mild, moderate- to-severe and sight-threatening forms can significantly compromise vision and quality of life. Advances in the understanding of TED pathophysiology \u2013 particularly the roles of orbital fibroblasts, thyrotropin receptor and insulin-like growth factor 1 receptor signalling\u2013 have transformed its diagnostic and therapeutic landscape. This manuscript provides a comprehensive and updated overview of epidemiology, risk factors, clinical presentation, diagnostic evaluation and management of TED. Current treatment strategies emphasize early risk-factor modification, restoration of euthyroidism, and a multidisciplinary approach tailored to disease activity and severity. Intravenous glucocorticoids remain the cornerstone of therapy for active moderate-to-severe disease, whereas adjunctive immunosuppressive agents and orbital radiotherapy are used in selected cases. The advent of targeted biologic therapies, particularly teprotumumab, as well as rituximab and tocilizumab, has significantly expanded therapeutic options and enabled a more personalized, phenotype-driven approach. Surgical rehabilitation continues to play a pivotal role in the inactive phase. Emerging therapies targeting novel molecular pathways hold promise for further improving patient outcomes. Despite these advances, challenges related to accessibility, cost, long-term safety and optimal patient selection persist. Ongoing research and international collaboration are expected to refine management strategies and enhance the quality of life of patients with TED.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-how-to-manage-thyroid-eye-disease-recent-advances-a-narrative-review\n\nThis article is part of the How to manage thyroid diseases: from autoimmunity to malignancy Special Issue: https:\/\/www.drugsincontext.com\/how-to-manage-thyroid-diseases-from-autoimmunity-to-malignancy<\/jats:p>","DOI":"10.7573\/dic.2026-4-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:27:55Z","timestamp":1788168475000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["How to manage thyroid eye disease: recent advances \u2013 a narrative review"],"prefix":"10.7573","author":[{"given":"Georgios K","family":"Markantes","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017wvtq80","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Patras"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Effraimidis","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04v4g9h31","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Thessaly"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Karapanou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00y1kmp77","id-type":"ROR","asserted-by":"publisher"}],"name":"NIMTS Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Saltiki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gnjpq42","id-type":"ROR","asserted-by":"publisher"}],"name":"National and Kapodistrian University of Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Michalaki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/017wvtq80","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Patras"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tWiersinga WM. Worldwide consensus on thyroid eye disease? What is in a name? Thyroid. 2022;32:1431\u20131433. https:\/\/doi.org\/10.1089\/thy.2022.29143.wie","DOI":"10.1089\/thy.2022.29143.wie"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tBurch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022;11(6):e220189. https:\/\/ doi.org\/10.1530\/ETJ-22-0189","DOI":"10.1530\/ETJ-22-0189"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tPerros P, Hegedus L, Bartalena L, et al. Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis. 2017;12:72. https:\/\/doi.org\/10.1186\/s13023-017-0625-1","DOI":"10.1186\/s13023-017-0625-1"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tRachmasari KN, Hamadi D, Thapa P, Bradley EA, Stan MN. The epidemiology of thyroid eye disease in Olmsted County, Minnesota, 2005\u20132020. Thyroid. 2024;34:1522\u20131530. https:\/\/doi.org\/10.1089\/thy.2024.0304","DOI":"10.1089\/thy.2024.0304"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tChin YH, Ng CH, Lee MH, et al. Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review. Clin Endocrinol. 2020;93(4):363\u2013374. https:\/\/doi.org\/10.1111\/cen.14296","DOI":"10.1111\/cen.14296"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tBartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol. 2020;11:615993. https:\/\/doi.org\/10.3389\/fendo.2020.615993","DOI":"10.3389\/fendo.2020.615993"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tKahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, K\u00f6nig J. Thyroid stimulating antibodies are highly prevalent in Hashimoto\u2019s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab. 2016;101(5):1998\u20132004. https:\/\/doi.org\/10.1210\/jc.2016-1220","DOI":"10.1210\/jc.2016-1220"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tWiersinga WM, Eckstein AK, \u017darkovi\u0107 M. Thyroid eye disease (Graves\u2019 orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025;13(7):600\u2013614. https:\/\/ doi.org\/10.1016\/S2213-8587(25)00066-X","DOI":"10.1016\/S2213-8587(25)00066-X"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tLee ACH, Kahaly GJ. Unravelling the pathogenic mechanisms in Graves\u2019 orbitopathy. Eur Thyroid J. 2025;14(5):e250200. https:\/\/doi.org\/10.1530\/ETJ-25-0200","DOI":"10.1530\/ETJ-25-0200"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tKulbay M, Tanya SM, Tuli N, et al. A comprehensive review of thyroid eye disease pathogenesis: from immune dysregulations to novel diagnostic and therapeutic approaches. Int J Mol Sci. 2024;25(21):11628. https:\/\/ doi.org\/10.3390\/ijms252111628","DOI":"10.3390\/ijms252111628"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tZhao S-X, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves\u2019 disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011;210:369\u2013377. https:\/\/ doi.org\/10.1530\/JOE-11-0162","DOI":"10.1530\/JOE-11-0162"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tMarcus-Samuels B, Krieger CC, Boutin A, Kahaly GJ, Neumann S, Gershengorn MC. Evidence that Graves\u2019 ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors. Thyroid. 2018;28:650\u2013655. https:\/\/ doi.org\/10.1089\/thy.2018.0089","DOI":"10.1089\/thy.2018.0089"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tKrieger CC, Neumann S, Gershengorn MC. Is there evidence for IGF1R-stimulating abs in Graves\u2019 orbitopathy pathogenesis? Int J Mol Sci. 2020;21:6561. https:\/\/doi.org\/10.3390\/ijms21186561","DOI":"10.3390\/ijms21186561"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tMoledina M, Damato EM, Lee V. The changing landscape of thyroid eye disease: current clinical advances and future outlook. Eye. 2024;38(8):1425\u20131437. https:\/\/doi.org\/10.1038\/s41433-024-02967-9","DOI":"10.1038\/s41433-024-02967-9"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tSmith TJ. Potential roles of CD34+ fibrocytes masquerading as orbital fibroblasts in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2019;104(2):581\u2013594. https:\/\/doi.org\/10.1210\/jc.2018-01493","DOI":"10.1210\/jc.2018-01493"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tAoun T, Danielova Gueorguieva D, Wu KY. Orbital inflammation in thyroid eye disease: stress responses and their implications. Stresses. 2024;4(1):54\u201378. https:\/\/doi.org\/10.3390\/stresses4010004","DOI":"10.3390\/stresses4010004"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tLiu J, Zhu T, Yang L, et al. Cigarette smoking drives thyroid eye disease progression via RAGE signaling activation. Thyroid. 2025;35(7):803\u2013815. https:\/\/doi.org\/10.1089\/thy.2025.0062","DOI":"10.1089\/thy.2025.0062"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\t\u015eahl\u0131 E, G\u00fcnd\u00fcz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94\u2013105. https:\/\/ doi.org\/10.4274\/tjo.80688","DOI":"10.4274\/tjo.80688"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tRana HS, Akella SS, Clabeaux CE, Skurski ZP, Aakalu VK. Ocular surface disease in thyroid eye disease: a narrative review. Ocul Surf. 2022;24:67\u201373. https:\/\/doi.org\/10.1016\/j.jtos.2022.02.001","DOI":"10.1016\/j.jtos.2022.02.001"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tBlandford AD, Zhang D, Chundury RV, Perry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Rev Ophthalmol. 2017;12(2):111\u2013121. https:\/\/doi.org\/10.1080\/17469899.2017.1276444","DOI":"10.1080\/17469899.2017.1276444"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tPatel P, Khandji J, Kazim M. Recurrent thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2015;31(6):445\u2013448. https:\/\/doi.org\/10.1097\/IOP.0000000000000371","DOI":"10.1097\/IOP.0000000000000371"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tWiersinga W, \u017darkovi\u0107 M, Bartalena L, et al. EUGOGO (European Group on Graves\u2019 Orbitopathy). Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism. Eur J Endocrinol. 2018;178:635\u2013643. https:\/\/doi.org\/10.1530\/EJE-18-0039","DOI":"10.1530\/EJE-18-0039"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tEckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464\u2013 3470. https:\/\/doi.org\/10.1210\/jc.2005-2813","DOI":"10.1210\/jc.2005-2813"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tTr\u00e4isk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves\u2019 hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700\u20133707. https:\/\/ doi.org\/10.1210\/jc.2009-0747","DOI":"10.1210\/jc.2009-0747"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tLanzolla G, Sabini E, Profilo MA, et al. Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study. J Endocrinol Invest. 2018;41:1417\u20131423. https:\/\/doi.org\/10.1007\/s40618-018-0915-z","DOI":"10.1007\/s40618-018-0915-z"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tBednarczuk T, Gopinath B, Ploski R, Wall JR. Susceptibility genes in Graves\u2019 ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol. 2007;67:3\u201319. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02854.x","DOI":"10.1111\/j.1365-2265.2007.02854.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tDolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthalmic Plast Reconstr Surg. 2006;22:319\u2013 324. https:\/\/doi.org\/10.1097\/01.iop.0000235499.34867.85","DOI":"10.1097\/01.iop.0000235499.34867.85"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tBarrio-Barrio J, Sabater AL, Bonet-Farriol E, Vel\u00e1zquez-Villoria \u00c1, Galofr\u00e9 JC. Graves\u2019 Ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015:249125. https:\/\/doi.org\/ 10.1155\/2015\/249125","DOI":"10.1155\/2015\/249125"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tFayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011;95:1670\u20131674. https:\/\/doi.org\/10.1136\/bjophthalmol-2011-300487","DOI":"10.1136\/bjophthalmol-2011-300487"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tPrummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy. Arch Intern Med. 1990;150:1098\u20131101. https:\/\/doi.org\/10.1001\/ archinte.1990.00390170124027","DOI":"10.1001\/archinte.1990.00390170124027"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tBadjrai RA, Eldinia LR, Anandi L, et al. Triamcinolone injection in the treatment of lid retraction for thyroid-associated ophthalmopathy: a systematic review. Eur J Ophthalmol. 2025;35:69\u201376. https:\/\/doi.org\/10.1177\/11206721241254405","DOI":"10.1177\/11206721241254405"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tYoung SM, Kim YD, Lang SS, Woo KI. Transconjunctival triamcinolone injection for upper lid retraction in thyroid eye disease \u2014 a new injection method. Ophthalmic Plast Reconstr Surg. 2018;34:587\u2013593. https:\/\/doi.org\/10.1097\/ IOP.0000000000001120","DOI":"10.1097\/IOP.0000000000001120"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tVillagelin D, Cooper DS, Burch HB. A 2023 international survey of clinical practice patterns in the management of Graves disease: a decade of change. J Clin Endocrinol Metab. 2024;109(11):2956\u20132966. https:\/\/doi.org\/10.1210\/ clinem\/dgae222","DOI":"10.1210\/clinem\/dgae222"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tBartalena L, Smith TJ. Treatment of hyperthyroidism in Graves\u2019 disease complicated by thyroid eye disease. J Clin Endocrinol Metab. 2025;110(4):922\u2013930. https:\/\/doi.org\/10.1210\/clinem\/dgaf009","DOI":"10.1210\/clinem\/dgaf009"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tWang J, Qin L. Radioiodine therapy versus antithyroid drugs in Graves\u2019 disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016;89(1064):20160418. https:\/\/doi.org\/10.1259\/bjr.20160418","DOI":"10.1259\/bjr.20160418"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tLiu X, Wong CKH, Wu T, et al. A comparison of cardiovascular disease, cancer, mortality, and Graves\u2019 ophthalmopathy following treatment for hyperthyroidism: a Bayesian network meta-analysis. World J Surg. 2024;48(2):393\u2013407. https:\/\/doi.org\/10.1002\/wjs.12066","DOI":"10.1002\/wjs.12066"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tBartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med. 1998;129:632\u2013635. https:\/\/doi.org\/10.7326\/0003-4819-129-8-199810150-00010","DOI":"10.7326\/0003-4819-129-8-199810150-00010"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tLaurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, T\u00f8rring O. TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69\u201375. https:\/\/doi.org\/10.1530\/EJE-07-0450","DOI":"10.1530\/EJE-07-0450"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tBartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy. Eur Thyroid J. 2016;5(1):9\u201326. https:\/\/ doi.org\/10.1159\/000443828","DOI":"10.1159\/000443828"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tWinther KH, Rayman MP, Bonnema SJ, Heged\u00fcs L. Selenium in thyroid disorders \u2014 essential knowledge for clinicians. Nat Rev Endocrinol. 2020;16(3):165\u2013176. https:\/\/doi.org\/10.1038\/s41574-019-0311-6","DOI":"10.1038\/s41574-019-0311-6"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"41.\tAhn HY, Lee MJ, Jung KY, et al. Selenium vs control for Graves ophthalmopathy in a selenium-sufficient area: a randomized clinical trial. JAMA Ophthalmol. 2025;143(4):287\u2013294. https:\/\/doi.org\/10.1001\/ jamaophthalmol.2024.6337","DOI":"10.1001\/jamaophthalmol.2024.6337"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tBartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","DOI":"10.1530\/EJE-21-0479"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tBartalena L, Krassas GE, Wiersinga W, et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2012;97:4454\u2013 4463. https:\/\/doi.org\/10.1210\/jc.2012-2389","DOI":"10.1210\/jc.2012-2389"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tZang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320\u2013332. https:\/\/doi.org\/10.1210\/jc.2010-1962","DOI":"10.1210\/jc.2010-1962"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tDouglas RS, Dailey R, Subramanian PS, et al. Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol. 2022;140:328\u2013335. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6284","DOI":"10.1001\/jamaophthalmol.2021.6284"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tEffraimidis G, Kasotas A, Bargiota A. Adrenal axis integrity after IV methylprednisolone therapy for thyroid eye disease: a retrospective cohort study. Eur J Endocrinol. 2026;194(5):653\u2013662. https:\/\/doi.org\/10.1093\/ejendo\/ lvag077","DOI":"10.1093\/ejendo\/lvag077"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tYe X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to severe Graves\u2019 orbitopathy. Clin Endocrinol. 2017;86(2):247\u2013255. https:\/\/doi.org\/10.1111\/cen.13170","DOI":"10.1111\/cen.13170"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tKahaly GJ, Riedl M, K\u00f6nig J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6:287\u2013298. https:\/\/doi.org\/10.1016\/S2213-8587(18)30020-2","DOI":"10.1016\/S2213-8587(18)30020-2"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tLi L-F, Xue J-L, Guan L, Su F-F, Wang H, Zhang D-F. Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid associated ophthalmopathy patients. Front Endocrinol. 2023;14:1140196. https:\/\/ doi.org\/10.3389\/fendo.2023.1140196","DOI":"10.3389\/fendo.2023.1140196"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tRajabi MT, Rafizadeh SM, Mohammadi A, et al. Mycophenolate mofetil (CellCept\u00ae) in combination with low dose prednisolone in moderate to severe Graves\u2019 orbitopathy. Front Med. 2022;9:788228. https:\/\/doi.org\/10.3389\/ fmed.2022.788228","DOI":"10.3389\/fmed.2022.788228"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tVannucchi G, Campi I, Covelli D, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid. 2021;31(5):821\u2013828. Erratum in: Thyroid. 2022;32(5):605. https:\/\/doi.org\/10.1089\/ thy.2020.0269","DOI":"10.1089\/thy.2020.0269.correx"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tKarasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves\u2019 orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017;68(5):498\u2013504. https:\/\/doi.org\/10.5603\/EP.a2017.0040","DOI":"10.5603\/EP.a2017.0040"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tCampi I, Vannucchi G, Muller I, et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves\u2019 orbitopathy. Front Endocrinol. 2022;12:790246. https:\/\/doi.org\/10.3389\/ fendo.2021.790246","DOI":"10.3389\/fendo.2021.790246"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tSalvi M, Vannucchi G, Curro N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422\u2013 431. https:\/\/doi.org\/10.1210\/jc.2014-3014","DOI":"10.1210\/jc.2014-3014"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tChen J, Chen G, Sun H. Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis. Hormones. 2021;20(2):279\u2013286. https:\/\/doi.org\/10.1007\/s42000-021-00282-6","DOI":"10.1007\/s42000-021-00282-6"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tMitchell AL, Gan EH, Morris M, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy. Clin Endocrinol. 2013;79(3):437\u2013442. https:\/\/ doi.org\/10.1111\/cen.12141","DOI":"10.1111\/cen.12141"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tStan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432\u2013441. https:\/\/doi.org\/10.1210\/jc.2014-2572","DOI":"10.1210\/jc.2014-2572"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tCopperman T, Idowu OO, Kersten RC, et al. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast Reconstr Surg. 2019;35(3):e64\u2013e66. https:\/\/doi.org\/10.1097\/IOP.0000000000001346","DOI":"10.1097\/IOP.0000000000001346"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tSilkiss RZ, Paap MK, Roelofs KA, et al. Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can J Ophthalmol. 2021;56(1):66\u201370. https:\/\/doi.org\/10.1016\/j.jcjo.2020.07.020","DOI":"10.1016\/j.jcjo.2020.07.020"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tLin S, Ou X, Cai L, Huang W, Wen J. Efficacy and safety of tocilizumab for thyroid eye disease: a systemic review and meta-analysis. J Endocrinol Invest. 2025;48(9):1951\u20131965. https:\/\/doi.org\/10.1007\/s40618-025-02595-4","DOI":"10.1007\/s40618-025-02595-4"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tDuarte AF, Xavier NF, Sales Sanz M, Cruz AAV. Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg. 2024;40(4):367\u2013373. https:\/\/doi.org\/10.1097\/ IOP.0000000000002573","DOI":"10.1097\/IOP.0000000000002573"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tAlves Junior JM, Bernardo W, Villagelin D. Effectiveness of different treatment modalities in initial and chronic phases of thyroid eye disease: a systematic review with meta-analysis. J Clin Endocrinol Metab. 2024;109(11):2997\u2013 3009. https:\/\/doi.org\/10.1210\/clinem\/dgae526","DOI":"10.1210\/clinem\/dgae526"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tPerez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u2013190. https:\/\/ doi.org\/10.1016\/j.ajo.2018.07.038","DOI":"10.1016\/j.ajo.2018.07.038"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tDalmas F, Foing C, Darrason G, et al. Long-term tocilizumab therapy in patients with corticosteroid-resistant active moderate-to-severe thyroid eye disease. Eur J Endocrinol. 2025;193(5):613\u2013621. https:\/\/doi.org\/10.1093\/ejendo\/ lvaf227","DOI":"10.1093\/ejendo\/lvaf227"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tDouglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","DOI":"10.1056\/NEJMoa1910434"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tDouglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129(4):438\u2013449. https:\/\/doi.org\/10.1016\/ j.ophtha.2021.10.017","DOI":"10.1016\/j.ophtha.2021.10.017"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tRosenblatt TR, Chiou CA, Yoon MK, Wolkow N, Lee NG, Freitag SK. Proptosis regression after teprotumumab treatment for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2024;40:187\u2013191. https:\/\/doi.org\/10.1097\/ IOP.0000000000002531","DOI":"10.1097\/IOP.0000000000002531"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"68.\tKahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid. 2024;34(7):880\u2013889. https:\/\/doi.org\/10.1089\/ thy.2023.0656","DOI":"10.1089\/thy.2023.0656"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tMen CJ, Amarikwa L, Pham B, et al. Teprotumumab for the treatment of recalcitrant thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2024;40:276\u2013285. https:\/\/doi.org\/10.1097\/IOP.0000000000002564","DOI":"10.1097\/IOP.0000000000002564"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tHwang CJ, Rebollo NP, Mechels KB, Perry JD. Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. 2024;263:152\u2013159. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001","DOI":"10.1016\/j.ajo.2023.12.001"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"71.\tDouglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109(1):25\u201335. https:\/\/doi.org\/10.1210\/clinem\/ dgad637","DOI":"10.1210\/clinem\/dgad637"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"72.\tNie T, Lamb YN. Teprotumumab: a review in thyroid eye disease. Drugs. 2022;82(17):1663\u20131670. https:\/\/ doi.org\/10.1007\/s40265-022-01804-1","DOI":"10.1007\/s40265-022-01804-1"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"73.\tStan MN, Krieger CC. The adverse effects profile of teprotumumab. J Clin Endocrinol Metab. 2023;108(9):e654\u2013 e662. https:\/\/doi.org\/10.1210\/clinem\/dgad213","DOI":"10.1210\/clinem\/dgad213"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"74.\tShah SA, Amarikwa L, Sears CM, et al. Teprotumumab-related adverse events in thyroid eye disease: a multicenter study. Ophthalmology. 2024;131(4):458\u2013467. https:\/\/doi.org\/10.1016\/j.ophtha.2023.10.018","DOI":"10.1016\/j.ophtha.2023.10.018"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"75.\tSears CM, Azad AD, Amarikwa L, et al. Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol. 2022;240:1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015","DOI":"10.1016\/j.ajo.2022.02.015"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"76.\tPerros P, Weightman DR, Crombie AL, Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol. 1990;122:8\u201312. https:\/\/doi.org\/10.1530\/acta.0.1220008","DOI":"10.1530\/acta.0.1220008"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"77.\tChalvatzis NT, Tzamalis AK, Kalantzis GK, El-Hindy N, Dimitrakos SA, Potts MJ. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. Eur J Ophthalmol. 2014;24:953\u2013959. https:\/\/doi.org\/10.5301\/ejo.5000463","DOI":"10.5301\/ejo.5000463"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"78.\tRajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 \u00d7 2 factorial, double-blind, randomized controlled trial. Lancet Diabetes Endocrinol. 2018;6:299\u2013309. https:\/\/doi.org\/10.1016\/S2213-8587(18)30021-4","DOI":"10.1016\/S2213-8587(18)30021-4"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"79.\tKahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest. 1986;16:415\u2013422. https:\/\/ doi.org\/10.1111\/j.1365-2362.1986.tb01016.x","DOI":"10.1111\/j.1365-2362.1986.tb01016.x"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"80.\tPrummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med. 1989;321:1353\u20131359. https:\/\/doi.org\/10.1056\/NEJM198911163212002","DOI":"10.1056\/NEJM198911163212002"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"81.\tStrianese D, Iuliano A, Ferrara M, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014;2014:128903. https:\/\/doi.org\/10.1155\/2014\/128903","DOI":"10.1155\/2014\/128903"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"82.\tLanzolla G, Maglionico MN, Comi S, et al. Sirolimus as a second line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest. 2022;45:2171\u20132180. https:\/\/doi.org\/10.1007\/s40618-022-01862-y","DOI":"10.1007\/s40618-022-01862-y"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tComi S, Cosentino G, Lanzolla G, et al. Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus. J Endocrinol Invest. 2025;48:607\u2013618. https:\/\/doi.org\/10.1007\/s40618-024-02470-8","DOI":"10.1007\/s40618-024-02470-8"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"84.\tRoos JCP, Murthy R. Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy. Eye. 2019;33:679\u2013682. https:\/\/doi.org\/10.1038\/s41433-019-0340-3","DOI":"10.1038\/s41433-019-0340-3"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"85.\tLanzolla G, Sabini E, Leo M, et al. Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 2021;9(11):733\u2013742. https:\/\/doi.org\/10.1016\/S2213- 8587(21)00238-2","DOI":"10.1016\/S2213-8587(21)00238-2"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"86.\tMalboosbaf R, Maghsoomi Z, Emami Z, Khamseh ME, Azizi F. Statins and thyroid eye disease (TED): a systematic review. Endocrine. 2024;85:11\u201317. https:\/\/doi.org\/10.1007\/s12020-023-03680-5.","DOI":"10.1007\/s12020-023-03680-5"},{"key":"ref86","unstructured":"87.\tViridian Therapeutics. Viridian Therapeutics announces positive topline results from veligrotug (VRDN-001) phase 3 THRIVE clinical trial in patients with active thyroid eye disease. https:\/\/investors.viridiantherapeutics. com\/news\/news-details\/2024\/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Veligrotug- VRDN-001-Phase-3-THRIVE-Clinical-Trial-in-Patients-with-Active-Thyroid-Eye-Disease\/default.aspx. Accessed April 7, 2026."},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tGulbins A, Horstmann M, Daser A, et al. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol. 2023;14:1211473. https:\/\/doi.org\/10.3389\/ fendo.2023.1211473","DOI":"10.3389\/fendo.2023.1211473"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tFurmaniak J, Sanders J, Sanders P, Li Y, Rees Smith B. TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy \u2013 results from a phase I clinical trial. Clin Endocrinol. 2022;96:878\u2013887. https:\/\/doi.org\/10.1111\/cen.14681","DOI":"10.1111\/cen.14681"},{"key":"ref89","unstructured":"90.\tSun G. GenSci098-a potent TSHR antagonistic antibody for the treatment of TED. https:\/\/www.eta2024.com\/files\/ download\/SHC-602.pdf. Accessed April 7, 2026."},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tlazaroni E, Covelli D, Curro N, et al. Comparison between the efficacy of the anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves\u2019 orbitopathy: an interim analysis. Endocrine Abstracts. 2020;70:YI9. https:\/\/doi.org\/10.1530\/endoabs.70.YI9","DOI":"10.1530\/endoabs.70.YI9"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tKahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab. 2023;108:3122\u20133134. https:\/\/doi.org\/10.1210\/clinem\/dgad381","DOI":"10.1210\/clinem\/dgad381"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"93.\tBehbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol. 2004;15(6):479\u2013482. https:\/\/doi.org\/10.1097\/01.icu.0000144388.89867.03","DOI":"10.1097\/01.icu.0000144388.89867.03"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tPrummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15\u201320. https:\/\/doi. org\/10.1210\/jc.2003-030809","DOI":"10.1210\/jc.2003-030809"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95.\tGorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology. 2001;108(9):1523\u20131534. https:\/\/doi.org\/10.1016\/ s0161-6420(01)00632-7","DOI":"10.1016\/S0161-6420(01)00632-7"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tBartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983;56(6):1139\u20131144. https:\/\/doi.org\/10.1210\/jcem-56-6-1139","DOI":"10.1210\/jcem-56-6-1139"},{"key":"ref96","unstructured":"97.\tNg CM, Yuen HK, Choi KL, et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves\u2019 ophthalmopathy: a preliminary study. Hong Kong Med J. 2005;11(5):322\u2013330."},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"98.\tShams PN, Ma R, Pickles T, et al. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157(6):1299\u20131305. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.044","DOI":"10.1016\/j.ajo.2014.02.044"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"99.\tKim SA, Jung SK, Paik JS, et al. Effect of orbital decompression on corneal topography in patients with thyroid ophthalmopathy. PLoS One. 2015;10(9):e0133612. https:\/\/doi.org\/10.1371\/journal.pone.0133612","DOI":"10.1371\/journal.pone.0133612"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"100.\tOeverhaus M, Witteler T, Lax H, et al. Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves\u2019 orbitopathy. Horm Metab Res. 2017;49(10):739\u2013 747. https:\/\/doi.org\/10.1055\/s-0043-116945","DOI":"10.1055\/s-0043-116945"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tCurr\u00f2 N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24:897\u2013905. https:\/\/doi.org\/10.1089\/thy.2013.0445","DOI":"10.1089\/thy.2013.0445"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"102.\tWakelkamp IMMJ, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial. Clin Endocrinol. 2005;63:323\u2013328. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02345.x","DOI":"10.1111\/j.1365-2265.2005.02345.x"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103.\tKazim M, Trokel S, Moore S. Treatment of acute Graves orbitopathy. Ophthalmology. 1991;98(9):1443\u20131448. https:\/\/ doi.org\/10.1016\/s0161-6420(91)32114-6","DOI":"10.1016\/S0161-6420(91)32114-6"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104.\tGold KG, Scofield S, Isaacson SR, et al. Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy. Ophthalmic Plast Reconstr Surg. 2018;34(2):172\u2013177. https:\/\/doi.org\/10.1097\/ IOP.0000000000001003","DOI":"10.1097\/IOP.0000000000001003"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105.\tTamhankar MA, Pradeep T, Chen Y, Brice\u00f1o CA. Real-world experience with teprotumumab in patients with dysthyroid optic neuropathy. J Neuroophthalmol. 2024;44:74\u201379. https:\/\/doi.org\/10.1097\/WNO.0000000000001994","DOI":"10.1097\/WNO.0000000000001994"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"106.\tHabroosh FA, Albrashdi SS, Alsaadi AH, Eatamadi H. Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort. Int Ophthalmol. 2024;44:222. https:\/\/doi.org\/10.1007\/s10792-024-03143-4","DOI":"10.1007\/s10792-024-03143-4"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"107.\tRootman DB. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63:86\u2013104. https:\/\/doi.org\/ 10.1016\/j.survophthal.2017.03.007","DOI":"10.1016\/j.survophthal.2017.03.007"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"108.\tTrokel S, Kazim M, Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology. 1993;100(5):674\u2013682. https:\/\/doi.org\/10.1016\/s0161-6420(93)31589-7","DOI":"10.1016\/S0161-6420(93)31589-7"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"109.\tLimawararut V, Valenzuela AA, Sullivan TJ, et al. Cerebrospinal fluid leaks in orbital and lacrimal surgery. Surv Ophthalmol. 2008;53(3):274\u2013284. https:\/\/doi.org\/10.1016\/j.survophthal.2008.02.009","DOI":"10.1016\/j.survophthal.2008.02.009"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"110.\tStahr K, Eckstein A, Buschmeier M, et al. Risk factors for new onset diplopia after graduated orbital decompression. Ophthalmic Plast Reconstr Surg. 2021;37(6):564\u2013570. https:\/\/doi.org\/10.1097\/IOP.0000000000001949","DOI":"10.1097\/IOP.0000000000001949"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"111.\tJellema HM, Saeed P, Mombaerts I, et al. Objective and subjective outcomes of strabismus surgery in Graves\u2019 orbitopathy: a prospective multicentre study. Acta Ophthalmol. 2017;95(4):386\u2013391. https:\/\/doi.org\/10.1111\/aos.13367","DOI":"10.1111\/aos.13367"},{"key":"ref111","unstructured":"112.\tKraus DJ, Bullock JD. Treatment of thyroid ocular myopathy with adjustable and nonadjustable suture strabismus surgery. Trans Am Ophthalmol Soc. 1993;91:67\u201379."},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"113.\tOeverhaus M, Fischer M, Hirche H, et al. Tendon elongation with bovine pericardium in patients with severe esotropia after decompression in Graves\u2019 orbitopathy \u2014 efficacy and long-term stability. Strabismus. 2018;26(2):62\u201370. https:\/\/doi.org\/10.1080\/09273972.2018.1450430","DOI":"10.1080\/09273972.2018.1450430"},{"key":"ref113","doi-asserted-by":"crossref","unstructured":"114.\tUgradar S, Wang Y, Douglas R. Teprotumumab for asymmetric thyroid eye disease. Ophthalmology. 2021;128:1416. https:\/\/doi.org\/10.1016\/j.ophtha.2021.03.004","DOI":"10.1016\/j.ophtha.2021.03.004"},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"115.\tArmeni AK, Markantes GK, Stathopoulou A, et al. Thyroid eye disease as initial manifestation of Graves\u2019 disease following viral vector SARS-CoV-2 vaccine: report of a case and review of the literature. Vaccines 2023;11(10):1574. https:\/\/doi.org\/10.3390\/vaccines11101574.","DOI":"10.3390\/vaccines11101574"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/08\/dic.2026-4-5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T09:28:20Z","timestamp":1788168500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/how-to-manage-thyroid-eye-disease-recent-advances-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":115,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-4-5","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"10.7573\/dic.2026-4-5"}}